Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZVS101e in Bietti's Crystalline Dystrophy
NCT05714904Phase 1Active, not recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Sep 2022
- Primary completion
- Jul 2025
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
Phase 1, open-label trial of ZVS101e in Bietti's crystalline dystrophy (BCD) (2 cohorts), sponsored by Peking University Third Hospital. Primary endpoint: Adverse Events and Serious Adverse Events at 104 weeks. Started Sep 2022; status: active, not recruiting.
02
Drugs
ZVS101e
03
Conditions
Bietti's crystalline dystrophy (BCD)
Beyond the preview
Go deeper on NCT05714904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05714904.